BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...autoimmune Clinical status: Preclinical Founded: 2019 by David Ting, Benjamin Greenbaum, Rosana Kapeller, Ari Nowacek, Bradley...
BioCentury | Feb 24, 2020
Distillery Therapeutics

DICER1 gene therapy for choroidal neovascularization

...et al. Proc. Natl. Acad. Sci. USA ; published online Jan. 21, 2020 doi:10.1073/pnas.1909761117 CONTACT: Bradley...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...gift from philanthropists Melanie and Richard Lundquist in February 2019. RedShift BioAnalytics Inc. hired Julien Bradley...
...therapeutics, also raised $18 million in a series D round backed by Waters Corp. (NYSE:WAT). Bradley...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

...before joining Merck & Co. Inc. (NYSE:MRK) as VP of discovery oncology in January. Co-founders Bradley...
...immune cell therapies for solid tumors Disease focus: Cancer Clinical status: Preclinical Founded: 2019 by Bradley...
BioCentury | Aug 22, 2018
Translation in Brief

Confirming CRISPR

...site. Those results aligned with a paper published last month in Nature Biotechnology from Allan Bradley’s...
...at Wellcome Sanger Institute that suggested CRISPR-Cas9 editing is prone to inducing large on-target deletions. Bradley...
BioCentury | Jul 16, 2018
Preclinical News

On-target mutations latest worry for CRISPR stocks

...the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s...
...cut the DNA, you are creating situations where the cell needs to repair that break," Bradley...
...added it would be difficult to control the endogenous repair mechanisms with existing technologies. Instead, Bradley...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Kymab’s work and that of its scientific founder and CSO Allan Bradley through connections between Bradley’s...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...online June 8, 2017 doi:10.1038/ncomms15711 CONTACT: Todd Bradley, Duke University Medical Center, Durham, N.C. email: todd.bradley@duke.edu...
BioCentury | Jul 14, 2017
Clinical News

FDA clears Amicus to submit migalastat NDA without new trial

...divisions at FDA that goes beyond his company’s experiences. On the call, President and COO Bradley...
BioCentury | Jul 12, 2017
Company News

FDA clears Amicus to submit migalastat NDA without new trial

...beyond his company’s experiences (see BioCentury, March 3) . On Tuesday's call, President and COO Bradley...
Items per page:
1 - 10 of 151
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...autoimmune Clinical status: Preclinical Founded: 2019 by David Ting, Benjamin Greenbaum, Rosana Kapeller, Ari Nowacek, Bradley...
BioCentury | Feb 24, 2020
Distillery Therapeutics

DICER1 gene therapy for choroidal neovascularization

...et al. Proc. Natl. Acad. Sci. USA ; published online Jan. 21, 2020 doi:10.1073/pnas.1909761117 CONTACT: Bradley...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...gift from philanthropists Melanie and Richard Lundquist in February 2019. RedShift BioAnalytics Inc. hired Julien Bradley...
...therapeutics, also raised $18 million in a series D round backed by Waters Corp. (NYSE:WAT). Bradley...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

...before joining Merck & Co. Inc. (NYSE:MRK) as VP of discovery oncology in January. Co-founders Bradley...
...immune cell therapies for solid tumors Disease focus: Cancer Clinical status: Preclinical Founded: 2019 by Bradley...
BioCentury | Aug 22, 2018
Translation in Brief

Confirming CRISPR

...site. Those results aligned with a paper published last month in Nature Biotechnology from Allan Bradley’s...
...at Wellcome Sanger Institute that suggested CRISPR-Cas9 editing is prone to inducing large on-target deletions. Bradley...
BioCentury | Jul 16, 2018
Preclinical News

On-target mutations latest worry for CRISPR stocks

...the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s...
...cut the DNA, you are creating situations where the cell needs to repair that break," Bradley...
...added it would be difficult to control the endogenous repair mechanisms with existing technologies. Instead, Bradley...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Kymab’s work and that of its scientific founder and CSO Allan Bradley through connections between Bradley’s...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...online June 8, 2017 doi:10.1038/ncomms15711 CONTACT: Todd Bradley, Duke University Medical Center, Durham, N.C. email: todd.bradley@duke.edu...
BioCentury | Jul 14, 2017
Clinical News

FDA clears Amicus to submit migalastat NDA without new trial

...divisions at FDA that goes beyond his company’s experiences. On the call, President and COO Bradley...
BioCentury | Jul 12, 2017
Company News

FDA clears Amicus to submit migalastat NDA without new trial

...beyond his company’s experiences (see BioCentury, March 3) . On Tuesday's call, President and COO Bradley...
Items per page:
1 - 10 of 151